Search

Your search keyword '"Non-Alcoholic Fatty Liver"' showing total 264,256 results

Search Constraints

Start Over You searched for: "Non-Alcoholic Fatty Liver" Remove constraint "Non-Alcoholic Fatty Liver"
264,256 results on '"Non-Alcoholic Fatty Liver"'

Search Results

201. Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.

202. Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research.

203. Serum untargeted metabolomics analysis of the preventive mechanism of TAETEA Prebiotea on non-alcoholic fatty liver in rats.

205. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.

206. The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease.

207. Comprehensive pharmacological and experimental study of Ginsenoside Re as a potential therapeutic agent for non-alcoholic fatty liver disease.

215. Serum bile acid and unsaturated fatty acid profiles of non-alcoholic fatty liver disease in type 2 diabetic patients.

218. Liver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys.

219. Pueraria lobata antioxidant extract ameliorates non-alcoholic fatty liver by altering hepatic fat accumulation and oxidative stress.

220. Vitamin E for people with non-alcoholic fatty liver disease.

221. High levels of serum hypersensitive C-reactive protein are associated with non-alcoholic fatty liver disease in non-obese people: a cross-sectional study.

222. Circulating fatty acids and risk of severe non-alcoholic fatty liver disease in the UK biobank: a prospective cohort of 116 223 individuals.

223. Advancing non-alcoholic fatty liver disease prediction: a comprehensive machine learning approach integrating SHAP interpretability and multi-cohort validation.

225. Evaluating the efficacy of GIPR agonists on non-alcoholic fatty liver disease: A Mediation Mendelian Randomization Study.

226. Vitamin A, C and E levels in patients with Non-Alcoholic Fatty Liver Disease: An Indian Cohort Study.

229. GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis.

230. Association between non-alcoholic fatty liver disease and metabolic abnormalities in children with different weight statuses.

231. Yellow tea polysaccharides protect against non-alcoholic fatty liver disease via regulation of gut microbiota and bile acid metabolism in mice.

232. Combined effects of sleep timing and nighttime sleep duration on non-alcoholic fatty liver disease.

233. Targeting histone methylation and demethylation for non-alcoholic fatty liver disease.

234. Meta-analysis of randomized controlled trials of the effects of synbiotics, probiotics, or prebiotics in controlling glucose homeostasis in non-alcoholic fatty liver disease patients.

235. Liver biopsy-proven non-alcoholic fatty liver disease predicts no impact on antiviral response in patients with chronic hepatitis B.

236. Dietary insulin index and dietary insulin load in relation to non-alcoholic fatty liver disease: a cross-sectional study.

237. Exposure to Succinate Leads to Steatosis in Non-Obese Non-Alcoholic Fatty Liver Disease by Inhibiting AMPK/PPARα/FGF21-Dependent Fatty Acid Oxidation.

238. Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease.

239. Study on the mechanism of Shenling Baizhu powder on the pathogenesis of pregnancy complicated with non-alcoholic fatty liver, based on PI3K/AKT/mTOR signal pathway.

240. Oxidative Stress and Annexin A2 Differential Expression in Free Fatty Acids-Induced Non-Alcoholic Fatty Liver Disease in HepG2 Cells.

241. Salvianolic acid A attenuates non-alcoholic fatty liver disease by regulating the AMPK-IGFBP1 pathway.

242. Role of oral hypoglycaemic drugs in preventing complication in non-alcoholic fatty liver disease with type 2 diabetes mellitus.

243. Bioinformatics analysis of potential ferroptosis and non-alcoholic fatty liver disease biomarkers.

245. A Medical Decision Support Platform for Identifying Thrombospondin 1 in Non-alcoholic Fatty Liver Disease via Immuno-Infiltration Analysis.

246. Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway.

247. Efficacy of the Mediterranean Diet Containing Different Macronutrients on Non-Alcoholic Fatty Liver Disease.

248. Effective roles of exercise and diet adherence in non-alcoholic fatty liver disease.

249. Pathogenic gene connections in type 2 diabetes and non-alcoholic fatty liver disease: a bioinformatics analysis and mouse model investigations experiments.

250. Strong association between sarcopenic obesity and non-alcoholic fatty liver disease: An observational study with ISarcoPRM algorithm.

Catalog

Books, media, physical & digital resources